 Home > Medical News > Medical Research Articles > Tianyan Pharmaceuticals announced that it will publish the clinical data of two new epitope original antibody projects in the form of posters at the ESMO conference in 2021

Tianyan Pharmaceuticals announced that it will publish the clinical data of two new epitope original antibody projects in the form of posters at the ESMO conference in 2021

 Last Update: 2022-01-04
 Source: Internet
 Author: User

Tags

treponema pallidum antibody

glass display jars

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

San Diego, USA and Suzhou, China, November 23, 2021/PRNewswire/ - Tianyan Pharmaceutical (hereinafter referred to as the "Company" or "Tianyan") (NASDAQ: ADAG) is a platform-driven clinic A stage biopharmaceutical company dedicated to discovering and developing new cancer immunotherapies based on original antibodies

The conference will be held in Geneva, Switzerland from December 8 to 11, 2021, and will be synchronized online and offline

" The clinical data of the NEObody® project of two new epitope antibodies that are being promoted demonstrates Tianyan's pioneering technology for unique epitopes and also reflects the antibody-antigen dynamic interaction mechanism

The specific information shown in the posters during ESMO-IO 2021 is as follows:

Title: Biomarker kinetic evaluation of ADG106 (anti-CD137 agonistic antibody) as a monotherapy or in combination with teriprizumab

Display Number: 43P

Title: Analysis of Phase I Dose-Climbing Trial Results of Original Anti-CTLA-4 Antibody ADG116 Single-drug Treatment for Patients with Advanced Solid Tumors

Display Number: 137P

ADG106 and ADG116 projects use Tianyan’s unique new epitope antibody NEObody™ technology, which can target highly conserved and unique epitopes against multiple antigens

About Tianyan Pharmaceutical

Tianyan Pharmaceutical (NASDAQ: ADAG) is a platform-driven biopharmaceutical company in the clinical product development stage with independent platform output.

For more information, please visit: https://investor.

Safe Harbor Statement

This press release contains forward-looking statements, including statements about the potential significance of clinical data to patients, clinical development plans and related clinical trial data, the potential benefits, safety and effectiveness of our partners’ products and investigational therapies, as well as Yanyao Industry advances and anticipates the preclinical activities, clinical development, regulatory milestones and commercialization of its candidate products

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Neopentyl Glycol CAS NO.126-30-7 99% High Quality Factory Supply

CAS No.: 126-30-7

Industrial Grade

$1.7-2/KG FOB

Factory Supply Tirzepatide 10 mg 15mg Weight Loss Peptide 10mg 99.9% CAS: 2023788-19-2

CAS No.: 2023788-19-2

Pharmacy Grade

$4-5/UNIT FOB

good quality 2cb wholesale

CAS No.: 58743-75-2

$2-2.2/MT EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.